Rational Design of Genetically Stable, Live-Attenuated Poliovirus Vaccines of All Three Serotypes: Relevance to Poliomyelitis Eradication
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The global eradication of poliomyelitis caused by wild-type virus is likely to be completed within the next few years, despite immense logistic and political difficulties, and may ultimately be followed by the cessation of vaccination. However, the existing live-attenuated vaccines have the potential to revert to virulence, causing occasional disease, and viruses can be shed by immunocompromised individuals for prolonged periods of time. Moreover, several outbreaks of poliomyelitis have been shown to be caused by viruses derived from the Sabin vaccine strains. The appearance of such strains depends on the prevailing circumstances but poses a severe obstacle to strategies for stopping vaccination. Vaccine strains that are incapable of reversion at a measurable rate would provide a possible solution. Here, we describe the constructions of strains of type 3 poliovirus that are stabilized by the introduction of four mutations in the 5′ noncoding region compared to the present vaccine. The strains are genetically and phenotypically stable under conditions where the present vaccine loses the attenuating mutation in the 5′ noncoding region completely. Type 1 and type 2 strains in which the entire 5′ noncoding regions of Sabin 1 and Sabin 2 were replaced exactly with that of one of the type 3 strains were also constructed. The genetic stability of 5′ noncoding regions of these viruses matched that of the type 3 strains, but significant phenotypic reversion occurred, illustrating the potential limitations of a rational approach to the genetic stabilization of live RNA virus vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A long-standing disadvantage of using OPVs is that attenuated vaccine strains can revert to a neuropathogenic phenotype during their replication in the intestinal tract [9,10,11,12,13,14].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are cases of paralytic polio due to the loss of viral attenuation in the oral poliovirus vaccine (OPV), known as vaccine-derived poliovirus (VDPV).”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, domV can be modified to alter viral virulence predictably and, at the same time, increase genetic stability to the extent that reversion is at undetectable levels (Macadam et al., 2006).”
From Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence (2020) · cites this paper as Macadam et al., 2006
The cited source says what the claim attributes to it.
In the citing paper
“These thermoresistant variants also display a significant increase in virulence (Macadam et al., 2006, Stern et al., 2017).”
From Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence (2020) · cites this paper as Macadam et al., 2006
The cited source says what the claim attributes to it.
In the citing paper
“S15domV did not revert, consistent with published data on the genetic stability of S15 (Macadam et al., 2006), but sequences showed gradual enrichment of a product with a Leon sequence.”
From Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence (2020) · cites this paper as Macadam et al., 2006
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vignuzzi, M., Stone, J. K., Arnold, J. J., Cameron, C. E., & Andino, R. (2006) · Nature · doi:10.1038/nature04388 · Cited by 1,116 · cited 1×
“It has recently been shown that a single substitution in poliovirus 3Dpol (G64S) decreased the rate of mutation threeto sixfold (42), with dramatic consequences on quasispecies diversity and tropism in vivo.”
BackgroundKew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., André, J., Blackman, E., Freeman, C. J., Jorba, J., et al. (2002) · Science · doi:10.1126/science.1068284 · Cited by 600 · cited 1×
“The first outbreak to be reported happened during 2000 and 2001 in Hispaniola, which had been certified free of polio in 1994 along with the rest of the countries in the Americas and which had a vaccination program of declining coverage, leading to the appearance of a vaccine-derived strain which could both cause dise…”
BackgroundEvans, D. M. A., Dunn, G., Minor, P. D., Schild, G. C., Cann, A. J., Stanway, G., Almond, J. W., Currey, K., & Maizel, J. V. (1985) · Nature · doi:10.1038/314548a0 · Cited by 440 · cited 1×
“genetically unstable as the virus replicates in recipients (5, 7, 8).”
BackgroundSelf-citationStrebel, P. M., Sutter, R. W., Cochi, S. L., Biellik, R. J., Brink, E. W., Kew, O. M., Pallansch, M. A., Orenstein, W. A., & Hinman, A. R. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.2.568 · Cited by 337
Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase.
van der Werf, S., Bradley, J., Wimmer, E., Studier, F. W., & Dunn, J. J. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.8.2330 · Cited by 337
One hundred years of poliovirus pathogenesis
Racaniello, V. R. (2006) · Virology · doi:10.1016/j.virol.2005.09.015 · Cited by 322 · cited 1×
“Over a period of 20 years, the molecular basis of the attenuation of the Sabin strains of poliomyelitis has been studied in detail (33).”
BackgroundSkinner, M. A., Racaniello, V. R., Dunn, G., Cooper, J., Minor, P. D., & Almond, J. W. (1989) · Journal of Molecular Biology · doi:10.1016/0022-2836(89)90261-1 · Cited by 297
Self-citationCirculating vaccine-derived polioviruses: current state of knowledge.
Kew, O. M., Wright, P. F., Agol, V. I., Delpeyroux, F., Shimizu, H., Nathanson, N., & Pallansch, M. A. (2004) · PubMed · doi:10.1590/s0042-96862004000100006 · Cited by 258
Brown, B., Oberste, M. S., Maher, K., & Pallansch, M. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8973-8984.2003 · Cited by 238 · cited 1×
“However, at this stage in the eradication of poliomyelitis, what is required in a live vaccine is complete genetic stability rather than improvement, however significant, and complete stability cannot be achieved for two reasons: domain V is not the only region containing determinants of attenuation, so reversion at o…”
BackgroundGenetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine
Westrop, G. D., Wareham, K. A., Evans, D. M., Dunn, G., Minor, P. D., Magrath, D. I., Taffs, F., Marsden, S., Skinner, M. A., & Schild, G. C. (1989) · Journal of Virology · doi:10.1128/jvi.63.3.1338-1344.1989 · Cited by 233
Self-citation
Research works printed but not linked: 1
- World Health Organization. 1983. Requirements for poliomyelitis vaccine (oral). WHO Tech. Rep. Ser. 687:107-175. [Google Scholar]
Cited by
Live attenuated vaccines: Historical successes and current challenges
Minor, P. D. (2015) · Virology · doi:10.1016/j.virol.2015.03.032 · Cited by 495
Self-citationEngineering attenuated virus vaccines by controlling replication fidelity
Vignuzzi, M., Wendt, E., & Andino, R. (2008) · Nature Medicine · doi:10.1038/nm1726 · Cited by 282
Polio vaccination: Past, present and future
Bandyopadhyay, A. S., Garon, J., Seib, K., & Orenstein, W. A. (2015) · Future Microbiology · doi:10.2217/fmb.15.19 · Cited by 276
Plotkin, S. A. (2009) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00290-09 · Cited by 256
Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence
Yeh, M. T., Bujaki, E., Dolan, P. T., Smith, M., Wahid, R., Konz, J., Weiner, A. J., Bandyopadhyay, A. S., Van Damme, P., De Coster, I., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.003 · Cited by 221
Self-citationBurns, C. C., Campagnoli, R., Shaw, J., Vincent, A., Jorba, J., & Kew, O. (2009) · Journal of Virology · doi:10.1128/jvi.00508-09 · Cited by 170
“Temperature sensitivity is a key phenotypic property of the Sabin OPV strains (33, 36, 41, 59) and other attenuated vaccine strains (3, 45, 56).”
BackgroundSutter, R. W., Kew, O. M., & Cochi, S. L. (2008) · Vaccines · doi:10.1016/b978-1-4160-3611-1.50030-1 · Cited by 167
Burns, C. C., Shaw, J., Jorba, J., Bukbuk, D., Adu, F., Gumede, N., Pate, M. A., Abanida, E. A., Gasasira, A., Iber, J., et al. (2013) · Journal of Virology · doi:10.1128/jvi.02954-12 · Cited by 153
Arita, M., Nagata, N., Iwata, N., Ami, Y., Suzaki, Y., Mizuta, K., Iwasaki, T., Sata, T., Wakita, T., & Shimizu, H. (2007) · Journal of Virology · doi:10.1128/jvi.02856-06 · Cited by 134
Blaney, J. E., Sathe, N. S., Goddard, L. B., Hanson, C. T., Romero, T. A., Hanley, K. A., Murphy, B. R., & Whitehead, S. S. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.11.082 · Cited by 113
Dunn, G., Klapsa, D., Wilton, T., Stone, L., Minor, P. D., & Martin, J. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005114 · Cited by 106
Self-citationBakker, W. A. M., Thomassen, Y. E., Oever, A. G. V. ’., Westdijk, J., van Oijen, M. G. C. T., Sundermann, L. C., Veld, P. V., Sleeman, E., van Nimwegen, F. W., Hamidi, A., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.079 · Cited by 107
Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization
Konopka-Anstadt, J. L., Campagnoli, R., Vincent, A., Shaw, J., Wei, L., Wynn, N. T., Smithee, S. E., Bujaki, E., Te Yeh, M., Laassri, M., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-0176-7 · Cited by 96
Self-citationPoliovirus Vaccine–Inactivated
Vidor, E. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00047-x · Cited by 94
Song, H., Ramírez, G., & Perez, D. R. (2007) · Journal of Virology · doi:10.1128/jvi.00893-07 · Cited by 90
Invasion thresholds and the evolution of nonequilibrium virulence
Bull, J. J., & Ebert, D. (2008) · Evolutionary Applications · doi:10.1111/j.1752-4571.2007.00003.x · Cited by 87
Development of an optimized RNA-based murine norovirus reverse genetics system
Yunus, M. A., Chung, L. M. W., Chaudhry, Y., Bailey, D., & Goodfellow, I. (2010) · Journal of Virological Methods · doi:10.1016/j.jviromet.2010.07.006 · Cited by 87
Sutter, R. W., Kew, O. M., Cochi, S. L., & Aylward, R. B. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00035-5 · Cited by 85
Vaccination against polio should not be stopped
Chumakov, K., Ehrenfeld, E., Wimmer, E., & Agol, V. I. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1769 · Cited by 87
Pliaka, V., Kyriakopoulou, Z., & Markoulatos, P. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.28 · Cited by 86
The final stages of the global eradication of poliomyelitis
Grassly, N. C. (2013) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2012.0140 · Cited by 80
Parker, E. P. K., Molodecky, N. A., Pons-Salort, M., O’Reilly, K. M., & Grassly, N. C. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1052800 · Cited by 77
The polio-eradication programme and issues of the end game
Minor, P. D. (2011) · Journal of General Virology · doi:10.1099/vir.0.036988-0 · Cited by 76
Self-citationShaw, A., Majumdar, M., Troman, C. M., O’Toole, Á., Benny, B., Abraham, D., Praharaj, I., Kang, G., Sharif, S., Alam, M. M., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00920-20 · Cited by 75
Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3
Yeh, M. T., Smith, M. R., Carlyle, S., Konopka‐Anstadt, J. L., Burns, C. C., Konz, J., Andino, R., & Macadam, A. J. (2023) · Nature · doi:10.1038/s41586-023-06212-3 · Cited by 66
Self-citationCoxsackieviruses and Quasispecies Theory: Evolution of Enteroviruses
Domingo, E., Martín, V., Perales, C., & Escarmís, C. (2008) · Springer eBooks · doi:10.1007/978-3-540-75546-3_1 · Cited by 65
Chumakov, K., & Ehrenfeld, E. (2008) · Clinical Infectious Diseases · doi:10.1086/593310 · Cited by 61
van der Sanden, S. M. G., Wu, W., Dybdahl-Sissoko, N., Weldon, W. C., Brooks, P., O’Donnell, J., Jones, L. P., Brown, C. J., Tompkins, S. M., Oberste, M. S., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01464-15 · Cited by 51
Kew, O. M., & Pallansch, M. A. (2018) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041749 · Cited by 49
Kalkowska, D. A., Pallansch, M. A., Wilkinson, A. L., Bandyopadhyay, A. S., Konopka‐Anstadt, J. L., Burns, C. C., Oberste, M. S., Wassilak, S. G. F., Badizadegan, K., & Thompson, K. M. (2020) · Risk Analysis · doi:10.1111/risa.13622 · Cited by 49
Poliomyelitis is a current challenge: long-term sequelae and circulating vaccine-derived poliovirus
Quarleri, J. F. (2022) · GeroScience · doi:10.1007/s11357-022-00672-7 · Cited by 46
Immunisation against poliomyelitis: moving forward
Ehrenfeld, E., Glass, R. I., Agol, V. I., Chumakov, K., Dowdle, W. R., John, T. J., Katz, S. L., Miller, M. D., Breman, J. G., Modlin, J. F., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60597-8 · Cited by 44
SAT2 Foot-and-Mouth Disease Virus Structurally Modified for Increased Thermostability
Scott, K. A., Kotecha, A., Seago, J. E., Ren, J., Fry, E. E., Stuart, D. I., Charleston, B., & Maree, F. F. (2017) · Journal of Virology · doi:10.1128/jvi.02312-16 · Cited by 43
Assessing the stability of polio eradication after the withdrawal of oral polio vaccine
Famulare, M., Selinger, C., McCarthy, K. A., Eckhoff, P. A., & Chabot‐Couture, G. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2002468 · Cited by 41
Verdijk, P., Rots, N. Y., & Bakker, W. A. M. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.51 · Cited by 39
Poliovirus vaccination during the endgame: insights from integrated modeling
Tebbens, R. J. D., & Thompson, K. M. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1322514 · Cited by 36
Knowlson, S., Burlison, J., Giles, E., Fox, H., Macadam, A. J., & Minor, P. D. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005316 · Cited by 35
Self-citationThe Fight against Poliovirus Is Not Over
Mbani, C. J., Nekoua, M. P., Moukassa, D., & Hober, D. (2023) · Microorganisms · doi:10.3390/microorganisms11051323 · Cited by 34
Sanders, B. P., Oakes, I. D. L. R., van Hoek, V., Bockstal, V., Kamphuis, T., Uil, T. G., Song, Y., Cooper, G., Crawt, L., Martín, J. E.-S., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005483 · Cited by 34
The risk of type 2 oral polio vaccine use in post-cessation outbreak response
McCarthy, K. A., Chabot‐Couture, G., Famulare, M., Lyons, H. M., & Mercer, L. D. (2017) · BMC Medicine · doi:10.1186/s12916-017-0937-y · Cited by 33
Sutter, R. W., Kew, O. M., Cochi, S. L., & Aylward, R. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00048-1 · Cited by 36
Wahid, R., Mercer, L. D., Macadam, A. J., Carlyle, S., Stephens, L., Martín, J. E.-S., Chumakov, K., Laassri, M., Petrovskaya, S. N., Smits, S. L., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00355-y · Cited by 30
Self-citationEvaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children
Wahid, R., Mercer, L. D., Gast, C., León, T. D., Sáez‐Llorens, X., Fix, A. D., Macadam, A. J., Stephens, L., Chumakov, K., Smits, S. L., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00437-5 · Cited by 28
Self-citationPeak, C. M., Lyons, H. M., Voorman, A., Gray, E., Cooper, L., Blake, I. M., Hawes, K. M., & Bandyopadhyay, A. S. (2024) · Vaccines · doi:10.3390/vaccines12121308 · Cited by 23
Wahid, R., Mercer, L. D., León, T. D., DeAntonio, R., Sáez‐Llorens, X., Macadam, A. J., Chumakov, K., Strating, J. R. P. M., Koel, B. F., Konopka‐Anstadt, J. L., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00254-3 · Cited by 22
Self-citationThe Potential Benefits of a new Poliovirus Vaccine for Long-Term Poliovirus Risk Management
Tebbens, R. J. D., & Thompson, K. M. (2016) · Future Microbiology · doi:10.2217/fmb-2016-0126 · Cited by 22
Outbreak response strategies with type 2-containing oral poliovirus vaccines
Kalkowska, D. A., Wassilak, S. G. F., Pallansch, M. A., Burns, C. C., Wiesen, E., Durry, E., Badizadegan, K., & Thompson, K. M. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.060 · Cited by 23
Kapusinszky, B., Molnár, Z., Szomor, K. N., & Berencsi, G. (2009) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2009.00621.x · Cited by 21
Sanders, B. P., Oakes, I. D. L. R., van Hoek, V., Liu, Y., Marissen, W. E., Minor, P. D., Wimmer, E., Schuitemaker, H., Custers, J. H. H. V., Macadam, A. J., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.091 · Cited by 19
Self-citationsIPV process development for costs reduction
Thomassen, Y. E., & Bakker, W. A. M. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.03.076 · Cited by 15
Alternative administration routes and delivery technologies for polio vaccines
Kraan, H., van der Stel, W., Kersten, G. F. A., & Amorij, J. (2016) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1158650 · Cited by 13
Lee, J. S., Kim, H. S., & Seo, S. H. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.043 · Cited by 12
Wang, R., Sun, Q., Xiao, J., Wang, C., Li, X., Li, J., Song, Y., Lu, H., Liu, Y., Zhu, S., et al. (2023) · Virus Research · doi:10.1016/j.virusres.2023.199268 · Cited by 11
Innovative IPV From Attenuated Sabin Poliovirus Or Newly Designed Alternative Seed Strains
Hamidi, A., & Bakker, W. A. M. (2012) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.12.70 · Cited by 11
Liang, J., Zhang, Q., Li, Y., & Wang, L. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1611028 · Cited by 10
Kew, O. M. (2014) · Springer eBooks · doi:10.1007/978-1-4899-7448-8_13 · Cited by 9
Shulman, L. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5719-0_10 · Cited by 7
Concepts of RNA virus evolution for the design of better antiviral countermeasures
Tran, Q.-T., & Vignuzzi, M. (2026) · Nature Reviews Microbiology · doi:10.1038/s41579-026-01316-9 · Cited by 6
Minor, P. D., Lane, B., Mimms, S., & Bar, P. (2017) · Biologicals · doi:10.1016/j.biologicals.2017.05.001 · Cited by 6
Self-citationMolecular Biology and Classification of Enteroviruses
Stanway, G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4051-2_12 · Cited by 6
Manukyan, H., Wahid, R., Ansari, A., Tritama, E., Macadam, A. J., Konz, J., Chumakov, K., & Laassri, M. (2022) · Vaccines · doi:10.3390/vaccines10091394 · Cited by 5
Self-citationPoliovirus Vaccine—Inactivated
Vidor, E. J., & Modlin, J. F. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00049-9 · Cited by 7
Shulman, L. M. (2012) · Springer eBooks · doi:10.1007/978-1-4419-0851-3_839 · Cited by 5
Estívariz, C. F., Burns, C. C., & Macklin, G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00050-5 · Cited by 7
Sabin Vaccine in Poliomyelitis Eradication: Achievements and Risks
Nafi, O., & Ramadan, B. (2019) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.13.1.45 · Cited by 4
Poliomyelitis: Concerns for polio-free countries
Arya, S. C., & Agarwal, N. (2007) · Vaccine · doi:10.1016/j.vaccine.2006.12.039 · Cited by 4
Manukyan, H., Lal, M., Zhu, C., Singh, O., Lin, T.-L., Tritama, E., Chumakov, K., Lee, S., & Laassri, M. (2024) · Viruses · doi:10.3390/v16060961 · Cited by 3
Manukyan, H., Tritama, E., Wahid, R., Konopka‐Anstadt, J. L., Konz, J., Chumakov, K., & Laassri, M. (2023) · Vaccines · doi:10.3390/vaccines11111729 · Cited by 3
RNA structures regulate norovirus life cycle and enable rational attenuation in vivo
Hann, T., Ökten, A. B., Filler, R. B., Wilen, C. B., & Pyle, A. M. (2026) · Cell · doi:10.1016/j.cell.2026.07.051 · Cited by 2
Las nuevas vacunas genéticamente atenuadas frente al virus de la poliomielitis
Reina, J., & Viana-Ramírez, J. (2024) · Vacunas · doi:10.1016/j.vacun.2024.10.003 · Cited by 2
The Development of Polio Vaccines: the Current Update (Review)
Ishmukhametov, A. A., Siniugina, A. A., & Chumakov, K. (2019) · Современные технологии в медицине · doi:10.17691/stm2019.11.4.22 · Cited by 2
Polio Vaccines: Present and Future
Chumakov, K., & Ishmukhametov, A. A. (2018) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2018-17-3-4-18 · Cited by 2
Manukyan, H., Tritama, E., Wahid, R., Ansari, A., Konz, J., Chumakov, K., & Laassri, M. (2021) · Vaccines · doi:10.3390/vaccines9070688 · Cited by 2
IPV v2.0 : upgrading the established inactivated polio vaccine production process
Thomassen, Y. E. (2014) · doi:10.18174/298149 · Cited by 2
Opmeer, L., Gazzoli, I., Ballmann, M. Z., Willemsen, M., Voshol, G. P., Grudniewska-Lawton, M., Havenga, M. J. E., Yallop, C., Hamidi, A., Gillissen, G. F., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.103 · Cited by 1
Insights on vaccine-derived poliovirus type 2 outbreaks and novel oral polio vaccine candidates
Aboshanab, K. M., Alshahrani, M. Y., Enshasy, H. A. E., Shabana, M. R., & Majeed, A. B. A. (2025) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2025.117221 · Cited by 1
Generation of Infectious Poliovirus with Altered Genetic Information from Cloned cDNA
Bujáki, E. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3292-4_12 · Cited by 1
Commonly setting biological standards in rare diseases
O’Connor, D. J., Buckland, J., Almond, N. M., Boyle, J., Coxon, C. H., Gaki, Ε., Martín, J. E.-S., Mattiuzzo, G., Metcalfe, C. L., Page, M., et al. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1652598 · Cited by 1
Palacios, G. F., Casas, I., & Trallero, G. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-04579-7.00153-2 · Cited by 1
Current Status and Future of Polio Vaccines and Vaccination
Chumakov, K. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1818-4_4 · Cited by 1
Андреевич, Л. В. (2013) · CyberLeninK (CyberLeninka)
Mattsson, J. (2012) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Kelly, J. T. (2015) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Stochastische Modellierung von Exitstrategien der Poliomyelitis
Krampol, M. (2007)
Shulman, L. M. (2020) · Springer eBooks · doi:10.1007/978-1-4939-2493-6_839-3
Rowlands, D. J., & Minor, P. D. (2014) · ASM Press eBooks · doi:10.1128/9781555816698.ch27
Self-citationREVIEW ON CURRENT POLIO VACCINES: VACCINATION SCHEDULES AND ADMINISTRATION ROUTES
Kumar, V. T. A. (2019) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.2656514
Shulman, L. M. (2023) · Encyclopedia of sustainability science and technology series · doi:10.1007/978-1-0716-2463-0_839
Kew, O. M. (2023) · Springer eBooks · doi:10.1007/978-1-4939-9544-8_13-1
The new genetically attenuated vaccines against poliomyelitis virus
Reina, J., & Viana-Ramírez, J. (2025) · Vacunas (English Edition) · doi:10.1016/j.vacune.2025.100381
Anti-poliovirus potential of botanicals and phytochemicals from African medicinal plants
Kuete, V., & Assonfack, D. J. (2026) · Advances in botanical research · doi:10.1016/bs.abr.2026.07.021
Subsets of intestinal dendritic cells and their role in orally-induced immune responses
Westlund, J. (2013) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Metadata
- Authors
- Macadam, A. J., Ferguson, G., Stone, D. M., Meredith, J., Knowlson, S., Auda, G., Almond, J. W., & Minor, P. D.
- Affiliations
- National Institute for Biological Standards and Control (GB)
- University of Reading (GB)
- Corresponding author
- Macadam, Andrew J.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2006-09
- Volume
- 80
- Issue
- 17
- Pages
- 8653-8663
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC1563845
- OpenAlex
- W2129812184
- Cited by
- 89
- References
- 44
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 8 · 2022: 5 · 2021: 2 · 2020: 5 · 2019: 3 · 2018: 3 · 2017: 6 · 2016: 4 · 2015: 8 · 2014: 3 · 2013: 5 · 2012: 6
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Evolution and Genetic Dynamics
- Keywords
- poliovirus, live attenuated vaccine, genetic stability, 5' untranslated region, type 3 poliovirus, Sabin vaccine strains, reversion to virulence, polio eradication
- MeSH terms
- Animals, Cell Line, Chlorocebus aethiops, Drug Stability, Genotype, Humans, L Cells, Mutation, Phenotype, Poliomyelitis, Serial Passage, Serotyping, Vaccines, Attenuated, Vero Cells, Virulence, Drug Design, Poliovirus, 5' Untranslated Regions, Poliovirus Vaccines, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.